⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431850 | 0.83 | — | — | |
| SCHEMBL11621900 | 0.79 | — | — | |
| SCHEMBL2373729 | 0.70 | — | — | |
| SCHEMBL3431240 | 0.69 | — | — | |
| SCHEMBL13213905 | 0.68 | — | — | |
| SCHEMBL3426417 | 0.68 | — | — | |
| SCHEMBL28012389 | 0.68 | — | — | |
| SCHEMBL10296349 | 0.68 | — | — | |
| SCHEMBL17377947 | 0.68 | — | — | |
| SCHEMBL16266638 | 0.68 | TRIM24 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1809557-B | Compound | ASTRAZENECA AB | 2012-07-04 | — | — | CN | disclosed |
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| CN-1809557-A | Compound | ASTRAZENECA AB (SE) | 2006-07-26 | — | — | CN | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |